The metabolic–dermatologic axis: Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide agonists as emerging immunometabolic therapies for obesity-associated skin disease. // Clinics in Dermatology. – URL: https://www.sciencedirect.com/science/article/pii/S0738081X26002932?dgcid=rss_sd_all
The metabolic–dermatologic axis: Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide agonists as emerging immunometabolic therapies for obesity-associated skin disease. Clinics in Dermatology. https://www.sciencedirect.com/science/article/pii/S0738081X26002932?dgcid=rss_sd_all
“The metabolic–dermatologic axis: Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide agonists as emerging immunometabolic therapies for obesity-associated skin disease.” Clinics in Dermatology.
@article{article41617,
title = {The metabolic–dermatologic axis: Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide agonists as emerging immunometabolic therapies for obesity-associated skin disease},
journal = {Clinics in Dermatology},
url = {https://www.sciencedirect.com/science/article/pii/S0738081X26002932?dgcid=rss_sd_all}
}